Key result
Enalapril produces similar serum ACE inhibition across single doses ranging from 2.5 to.
Why the study?
The relationship between oral dose of enalapril and serum ACE inhibition parameters in normotensive volunteers was unclear.
Answers are grounded in this paper and cite their sources.
Dose-response data from healthy volunteers warrant no change in enalapril use; leaves open ACE inhibition relationships in patients with hypertension or HF.
OBJECTIVES: To determine the relationship between oral dose of enalapril and parameters describing serum angiotensin converting enzyme (ACE) inhibition. METHODS: Four different oral doses of enalapril maleate (2.5, 5, 10 and 20 mg) were administered to six healthy normotensive volunteers, in a four-period crossover study. Serum ACE inhibition profiles were determined in each case using a synthetic substrate, hippuryl-histidyl-leucine (HHL). Pharmacodynamic parameters of the drug (Emax and AUEC0-->24) were calculated and their relationship to oral doses investigated using linear regression analysis. RESULTS: There was no significant relationship between drug dose and the two pharmacodynamic parameters (Emax and AUEC0-->24). The r2 values were 0.548 (F=3.63, P=0.153) and 0.6360 (F=5.24, P=0.106) for Emax and AUEC0-->24, respectively. CONCLUSION: The extent of serum ACE inhibition, as the main determinant of the blood pressure lowering effect of enalapril, is not dose-dependent within the single dose range of 2.5-20 mg.
No takes yet. Share an insight, caveat, or question.
Rouini et al. (2002) studied Healthy normotensive volunteers (n=6). Enalapril maleate was evaluated on Pharmacodynamic parameters of serum ACE inhibition (Emax and AUEC0-->24) (r2 0.548 for Emax, r2 0.6360 for AUEC0-->24, p=0.153 for Emax, 0.106 for AUEC0-->24). The extent of serum ACE inhibition by enalapril maleate was not dose-dependent within the single dose range of 2.5-.
Synapse has enriched 10 related papers. Consider them for comparative context: